Alterations of Fas and Fas-related molecules in patients with silicosis

Experimental Biology and Medicine

Volumn 231, Issue 5, 2006, Pages 522-533

  Otsuki, Takemi ^a   Miura, Yoshie ^a   Nishimura, Yasumitsu ^a   Hyodoh, Fuminori ^a   Takata, Akiko ^a   Kusaka, Masayasu ^b   Katsuyama, Hironobu ^a   Tomita, Masafumi ^a   Ueki, Ayako ^c   Kishimoto, Takumi ^d  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Kusaka Hospital   (Japan)

^c KAWASAKI UNIVERSITY OF MEDICAL WELFARE   (Japan)

^d Japan Labour Health and Welfare Organization   (Japan)

Author keywords

Apoptosis; Autoimmunity; Fas; Silicosis

Indexed keywords

AUTOANTIBODY; CASP8 PROTEIN, HUMAN; CASPASE; CASPASE 8; FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR;

GENETICS; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SILICOSIS;

ANTIGENS, CD95; AUTOANTIBODIES; CASPASE 8; CASPASES; FAS LIGAND PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; SIGNAL TRANSDUCTION; SILICOSIS; TUMOR NECROSIS FACTORS;

EID: 33744991533     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/153537020623100506     Document Type: Short Survey

References (85)

1. Iannello S, Camuto M, Cantarella S, Cavaleri A, Ferriero P, Leanza A, Milazzo P, Belfiore F. Rheumatoid syndrome associated with lung interstitial disorder in a dental technician exposed to ceramic silica dust: a case report and critical literature review. Clin Rheumatol 21:76-81, 2002.
2. Stratta P, Canavese C, Messuerotti A, Fenoglio I, Fubini B. Silica and renal diseases: no longer a problem in the 21st century? J Nephrol 14: 228-247, 2001.
3. Shanklin DR, Smalley DL. The immunopathology of siliconosis: history, clinical presentation, and relation to silicosis and the chemistry of silicon and silicone. Immunol Res 18:125-173, 1998.
4. Steenland K, Goldsmith DF. Silica exposure and autoimmune diseases. Am J Ind Med 28:603-608, 1995.
5. Uber CL, McReynolds RA. Immunotoxicology of silica. Crit Rev Toxicol 10:303-319 1982.
6. Benedek TG. Rheumatoid pneumoconiosis: documentation of onset and pathogenic considerations. Am J Med 55:515-524, 1973.
7. Scarisbrick D. Silicosis and coal workers' pneumoconiosis. Practitioner 246:114, 117-9, 2002.
8. Ondrasik M. Caplan's syndrome. Baillieres Clin Rheumatol 3:205-210, 1989.
9. Constantinidis K. Pneumoconiosis and rheumatoid arthritis (Caplan's syndrome). Br J Clin Pract 31:25-31, 1977.
10. Sluis-Cremer GK. Respiratory manifestations of rheumatoid arthritis. S Afr Med J 44:843-846, 1970.
11. Bar-Meir E, Eherenfeld M, Shoenfeld Y. Silicone gel breast implants and connective tissue disease - a comprehensive review. Autoimmunity 36:193-197, 2003.
12. Brown SL, Langone JJ, Brinton LA. Silicone breast implants and autoimmune disease. J Am Med Womens Assoc 53:21-24, 1998.
13. Reyes H, Ojo-Amaize EA, Peter JB. Silicates, silicones and autoimmunity. Isr J Med Sci 33:239-242, 1997.
14. Blackburn WD Jr, Everson MP. Silicone-associated rheumatic disease: an unsupported myth. Plast Reconstr Surg 99:1362-1367, 1997.
15. Endo LP, Edwards NL, Longley S, Corman LC, Panush RS. Silicone and rheumatic diseases. Semin Arthritis Rheum 17:112-118, 1987.
16. Guthrie GD Jr. Mineral properties and their contributions to particle toxicity. Environ Health Perspect 105(Suppl 5):1003-1011, 1997.
17. De Vuyst P. Biopersistence of respirable synthetic fibers and minerals: point of view of the chest physician. Environ Health Perspect 102(Suppl 5):7-9, 1994.
18. Wylie AG, Bailey KF, Kelse JW, Lee RJ. The importance of width in asbestos fiber carcinogenicity and its implications for public policy. Am Ind Hyg Assoc J 54:239-252, 1993.
19. Gaensler EA, Addington WW. Asbestos or ferruginous bodies. N Engl J Med 280:488-492, 1969.
20. Rom WN, Palmer PE. The spectrum of asbestos-related diseases. West J Med 121:10-21, 1974.
21. Weill H, Hughes JM. Asbestos as a public health risk: disease and policy. Annu Rev Public Health 7:171-192, 1986.
22. Steenland K, Stayner L. Silica, asbestos, man-made mineral fibers, and cancer. Cancer Causes Control 8:491-503, 1997.
23. Tweedale G. Asbestos and its lethal legacy. Nat Rev Cancer 2:311-315, 2002.
24. Hughes RS. Malignant pleural mesothelioma. Am J Med Sci 329:29-44, 2005.
25. Hessel PA, Gamble JF, McDonald JC. Asbestos, asbestosis, and lung cancer: a critical assessment of the epidemiological evidence. Thorax 60:433-436, 2005.
26. Pernis B, Paronetto F. Adjuvant effect of silica (tridymite) on antibody production. Proc Soc Exp Biol Med 110:390-392, 1962.
27. Myrvik QN. Adjuvants. Ann N Y Acad Sci 221:324-330, 1974.
28. Mancino D, Bevilacqua N. Adjuvant effect of amorphous silica on the immune response to various antigens in guinea pigs. Int Arch Allergy Appl Immunol 53:97-103, 1977.
29. Mancino D, Bevilacqua N. Further studies on the adjuvant effect of silica on IgE antibody production in mice. Int Arch Allergy Appl Immunol 59:427-431, 1979.
30. Bramm E, Binderup L, Arrigoni-Martelli E. Inhibition of adjuvant arthritis by intraperitoneal administration of low doses of silica. Agents Actions 10:435-438, 1980.
31. Lappe MA. Silicone-reactive disorder: a new autoimmune disease caused by immunostimulation and superantigens. Med Hypotheses 41: 348-352, 1993.
32. Parks CG, Conrad K, Cooper GS. Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 107(Suppl 5): 793-802, 1999.
33. Davis GS, Holmes CE, Pfeiffer LM, Hemenway DR. Lymphocytes, lymphokines, and silicosis. J Environ Pathol Toxicol Oncol 20(Suppl 1):53-65, 2001.
34. Nagata S. Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos Trans R Soc Lond B Biol Sci 345:281-287, 1994.
35. Lynch DH. Biology of Fas. Circ Shock 44:63-66, 1994.
36. Nagata S. Fas-induced apoptosis. Intern Med 37:179-181, 1998.
37. Krueger A, Fas SC, Baumann S, Krammer PH. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev 193:58-69, 2003.
38. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 193:70-81, 2003.
39. Li-Weber M, Krammer PH. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 15:145-157, 2003.
40. Nagata S, Golstein P. The Fas death factor. Science 267:1449-1456, 1995.
41. Rudin CM, Van Dongen J, Thompson CB. Apoptotic signaling in lymphocytes. Curr Opin Hematol 3:35-40, 1996.
42. Lenardo MJ. Molecular regulation of T lymphocyte homeostasis in the healthy and diseased immune system. Immunol Res 27:387-398, 2003.
43. Prasad KV, Prabhakar BS. Apoptosis and autoimmune disorders. Autoimmunity 36:323-330, 2003.
44. Cohen PL, Eisenberg RA. The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane. Immunol Today 13: 427-428, 1992.
45. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39-43, 1995.
46. Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. J Hum Genet 43:2-8, 1998.
47. Yonehara S. Effects of anti-Fas antibodies on lymphocytes and other organs: preparation of original and new monoclonal antibodies and amelioration of systemic autoimmune disease. Int Rev Immunol 18: 329-345, 1999.
48. Guidelines for the Use of the ILO International Classification of Radiographs of Pneumoconioses (revised ed.). Geneva, Switzerland: International Labour Organization, 2000.
49. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 15:185-193, 2003.
50. Sheikh MS, Huang Y. The FADD is going nuclear. Cell Cycle 2:346-347, 2003.
51. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10:26-35, 2003.
52. Widlak P. The DFF40/CAD endonuclease and its role in apoptosis. Acta Biochim Pol 47:1037-1044, 2000.
53. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 256:12-18, 2000.
54. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762, 1994.
55. Jodo S, Kobayashi S, Kayagaki N, Ogura N, Feng Y, Amasaki Y, Fujisaku A, Azuma M, Yagita H, Okumura K, Koike T. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 107:89-95, 1997.
56. Rose LM, Latchman DS, Isenberg DA. Elevated soluble fas production in SLE correlates with HLA status not with disease activity. Lupus 6: 717-722, 1997.
57. Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, McFarland HF, Martin R. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann Neurol 3: 116-120, 1998.
58. Tomokuni A, Aikoh T, Matsuki T, Isozaki Y, Otsuki T, Kita S, Ueki H, Kusaka M, Kishimoto T, Ueki A. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol 110:303-309, 1997.
59. Tomokuni A, Otsuki T, Isozaki Y, Kita S, Ueki H, Kusaka M, Kishimoto T, Ueki A. Serum levels of soluble Fas ligand in patients with silicosis. Clin Exp Immunol 118:441-444, 1999.
60. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 61:577-581, 2001.
61. Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Kimura T. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 28:22-28, 2001.
62. Otsuki T, Sakaguchi H, Tomokuni A, Aikoh T, Matsuki T, Kawakami Y, Kusaka M, Ueki H, Kita S, Ueki A. Soluble Fas mRNA is dominantly expressed in cases with silicosis. Immunology 94:258-262, 1998.
63. Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y, Hyodoh F, Ueki H, Kusaka M, Kita S, Ueki A. Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. Clin Exp Immunol 119:323-327, 2000.
64. Guo Z-Q, Otsuki T, Shimizu T, Tachiyama S, Sakaguchi H, Isozaki Y, Tomokuni T, Hyodoh F, Kusaka M, Ueki A. Reduced expression of survivin gene in PBMC from silicosis patients. Kwasaki Med J 27: 75-81, 2001.
65. Otsuki T, Tomokuni A, Sakaguchi H, Hyodoh F, Kusaka M, Ueki A. Reduced expression of the inhibitory genes for Fas-mediated apoptosis in silicosis patients. J Occup Health 42:163-168, 2000.
66. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699-703, 1998.
67. Otsuki T, Sakaguchi H, Tomokuni A, Aikoh T, Matsuki T, Isozaki Y, Hyodoh F, Kawakami Y, Kusaka M, Kita S, Ueki A. Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients. Immunol Lett 72: 137-143, 2000.
68. Otsuki T, Ichihara K, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y, Hyodoh F, Kusaka M, Kita S, Ueki A. Evaluation of cases with silicosis using the parameters related to Fas-mediated apoptosis. Int J Mol Med 4:407-411, 1999.
69. Dosreis GA, Borges VM, Zin WA. The central role of Fas-ligand cell signaling in inflammatory lung diseases. J Cell Mol Med 8:285-293, 2004.
70. Hagimoto N, Kuwano K, Miyazaki H, Kunitake R, Fujita M, Kawasaki M, Kaneko Y, Hara N. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol 17:272-278, 1997.
71. Chapman HA. A Fas pathway to pulmonary fibrosis. J Clin Invest 104: 1-2, 1999.
72. Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S, Suda T, Kunitake R, Maeyama T, Miyazaki H, Hara N. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 104:13-19, 1999.
73. Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 16:91-101, 1997.
74. Ueki A. Biological effects of asbestos fibers on human cells in vitro - especially on lymphocytes and neutrophils. Ind Health 39:84-93, 2001.
75. Borges VM, Falcao H, Leite-Junior JH, Alvim L, Teixeira GP, Russo M, Nobrega AF, Lopes MF, Rocco PM, Davidson WF, Linden R, Yagita H, Zin WA, DosReis GA. Fas ligand triggers pulmonary silicosis. J Exp Med 194:155-164, 2001.
76. Hamzaoui A, Ammar J, Grairi H, Hamzaoui K. Expression of Fas antigen and Fas ligand in bronchoalveolar lavage from silicosis patients. Mediators Inflamm 12:209-214, 2003.
77. Dosreis GA, Borges VM, Zin WA. The central role of Fas-ligand cell signaling in inflammatory lung diseases. J Cell Mol Med 8:285-293, 2004.
78. Ueki A, Isozaki Y, Tomokuni A, Otsuki T, Hydoh F, Sakaguchi H, Tanaka S, Kusaka M. Is the anti-topoisomerase I autoantibody response associated with a distinct amino acid sequence in the HLA-DQbeta1 domain? Arthritis Rheum 44:491-492, 2001.
79. Tomokuni A, Otsuki T, Sakaguchi H, Isozaki Y, Hyodoh F, Kusaka M, Ueki A. Detection of Anti-topoisomerase I autoantibody in patients with silicosis. Environ Health Prev Med 7:7-10, 2002.
80. Ueki A, Isozaki Y, Tomokuni A, Ueki H, Kusaka M, Tanaka S, Otsuki T, Sakaguchi H, Hyodoh F. Different distribution of HLA class II alleles in anti-topoisomerase I autoantibody responders between silicosis and systemic sclerosis patients, with a common distinct amino acid sequence in the HLA-DQB1 domain. Immunobiology 204:458-465, 2001.
81. Ueki H, Kohda M, Nobutoh T, Yamaguchi M, Omori K, Miyashita Y, Hashimoto T, Komai A, Tomokuni A, Ueki A. Antidesmoglein autoantibodies in silicosis patients with no bullous diseases. Dermatology 202:16-21, 2001.
82. Ueki A, Isozaki Y, Tomokuni A, Hatayama T, Ueki H, Kusaka M, Shiwa M, Arikuni H, Takeshita T, Morimoto K. Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals. Clin Exp Immunol 129:556-561, 2002.
83. Takata-Tomokuni A, Ueki A, Shiwa M, Isozaki Y, Hatayama T, Katsuyama H, Hyodoh F, Fujimoto W, Ueki H, Kusaka M, Arikuni H, Otsuki T. Detection, epitope-mapping, and function of anti-Fas autoantibody in patients with silicosis. Immunology 116:21-29, 2005.
84. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M, Namba M. Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haemato 73:199-204, 1989.
85. Otsuki T, Hata H, Harada N, Matsuzaki H, Yata K, Wada H, Yawata Y, Ueki A, Yamada O. Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient. Int J Hematol 72:216-222, 2000.